Evidence map›Paper›PMID 38337034›Full record

ReviewNature reviews. Microbiology2024

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure.

Marie Armani-Tourret, Benjamin Bone, Toong Seng Tan, Weiwei Sun, Maxime Bellefroid, Tine Struyve, Michael Louella, Xu G Yu, Mathias Lichterfeld

Abstract readReview
In one paragraph

Review in Nature reviews. Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Searching for a HIV-1 Cure.Theranostics · 2026
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marie Armani-TourretInfectious Disease Division, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0009-0008-8734-8400
Benjamin BoneInfectious Disease Division, Brigham and Women's Hospital, Boston, MA, USA.
Toong Seng TanInfectious Disease Division, Brigham and Women's Hospital, Boston, MA, USA.
Weiwei SunInfectious Disease Division, Brigham and Women's Hospital, Boston, MA, USA.
Maxime BellefroidInfectious Disease Division, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0019-9913
Tine StruyveHIV Cure Research Center, Ghent University, Ghent, Belgium.
Michael LouellaCommunity Advisory Board, Delaney AIDS Research Enterprise (DARE), San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4057-9494
Xu G YuInfectious Disease Division, Brigham and Women's Hospital, Boston, MA, USA.
Mathias LichterfeldInfectious Disease Division, Brigham and Women's Hospital, Boston, MA, USA. mlichterfeld@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-9865-8350

Funding

Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5M
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
A Pilot Clinical Trial for HIV-1 EradicationU01AI117841 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2015 to 2020
$10.7M
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in BotswanaU01AI135940 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2018 to 2024
$10.4M
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3P01AI169768 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Athe M. Tsibris · 2022 to 2026
$10.1M
Tsepamo Plus: Expanded Congenital Abnormalities Surveillance with an Emulated Clinical Trial to Evaluate Weight Impact on Birth Outcomes for Newer ART RegimensP01HD107670 · NICHD · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI SHAPIRO, ROGER L · 2021 to 2025
$6.1M
Elite controllers as a model for a cure of HIV-1 infectionR37AI155171 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Xu Yu · 2020 to 2026
$5.2M
Single-cell Proteogenomic profiling of HIV-1 reservoir cellsR01AI176579 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Mathias Lichterfeld · 2023 to 2026
$4.6M
Immunoregulatory Function of Myelomonocytic Receptors in HIV-1 InfectionR01AI078799 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2008 to 2017
$4.1M
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodesR01DK120387 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI LICHTERFELD, MATHIAS, YUKL, STEVEN A · 2019 to 2023
$4.1M
NHLBI NIH HHS R01 HL134539NIAID NIH HHS K24 AI155233NIAID NIH HHS P01 AI169768NIAID NIH HHS R01 AI078799NIAID NIH HHS R01 AI130005NIAID NIH HHS R01 AI152979NIAID NIH HHS R01 AI176579NIAID NIH HHS R01 AI184094NIAID NIH HHS R21 AI116228NIAID NIH HHS R33 AI116228NIAID NIH HHS R37 AI155171NIAID NIH HHS U01 AI117841NIAID NIH HHS U01 AI135940NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164562NIAID NIH HHS UM1 AI164566NIAID NIH HHS UM1 AI164570NICHD NIH HHS P01 HD107670NIDA NIH HHS R33 DA047034NIDA NIH HHS R61 DA047034NIDDK NIH HHS R01 DK120387
6 · The paper itself

Abstract

Successful approaches for eradication or cure of HIV-1 infection are likely to include immunological mechanisms, but remarkably little is known about how human immune responses can recognize and interact with the few HIV-1-infected cells that harbour genome-intact viral DNA, persist long term despite antiretroviral therapy and represent the main barrier to a cure. For a long time regarded as being completely shielded from host immune responses due to viral latency, these cells do, on closer examination with single-cell analytic techniques, display discrete footprints of immune selection, implying that human immune responses may be able to effectively engage and target at least some of these cells. The failure to eliminate rebound-competent virally infected cells in the majority of persons likely reflects the evolution of a highly selected pool of reservoir cells that are effectively camouflaged from immune recognition or rely on sophisticated approaches for resisting immune-mediated killing. Understanding the fine-tuned interplay between host immune responses and viral reservoir cells will help to design improved interventions that exploit the immunological vulnerabilities of HIV-1 reservoir cells.

Indexed as

HIV-1HIV InfectionsVirus LatencyCD4-Positive T-LymphocytesHumans

Identifiers

PMID38337034
PMCPMC11131351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.